Whereas many studies investigated the diagnostic accuracy of CSF tau using patients with AD that had initially been suspected as sCJD, we analyzed CSF from rpAD patients that were part of an independent study on AD, reflecting the spectrum of AD in a non-specialized center. This evidence concerns the gene MAPT and Alzheimer disease.